Comparing the current results to its competitors, Manhattan Scientifics Inc reported Revenue decrease in the 2 quarter 2024 year on year by 0 %, despite the revenue increase by the most of its competitors of 4 %, recorded in the same quarter.
Manhattan Scientifics Inc , slower than the average decrease reported by the company's competitors of -5.3 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -5.3 %
Manhattan Scientifics Inc 's Comment on Competition and Industry Peers
The company holds licensed technology in its advanced materials operations, resulting in no direct competitors in that area. In the nanomedicine sector, specifically cancer detection, the company competes with Abbott Laboratories Inc., Cepheid Inc., Philips, GE Healthcare, Siemens, Gen-Probe Incorporated, MDxHealth SA, EpiGenomics AG, Roche Diagnostics, and Sequenom, Inc. Competitors may challenge the company's licensed technology, develop similar non-infringing products, or operate in regions without the company's intellectual property protection. Many competitors have longer operating histories and greater financial, marketing, and other resources, and may introduce new products targeting the company's potential markets. Key competitive factors include capitalization, product cost, speed to market, intellectual property strength, and product reliability.
Publicly Traded Peers of Manhattan Scientifics Inc
Abbott Laboratories Share Performance
+0.34%
30 Days
Abbott Laboratories
Profile
Abbott Laboratories operates as a diversified healthcare company with a focus on developing and manufacturing a wide range of health-related products, including pharmaceuticals, medical devices, nutritional products, and diagnostic technologies. Their business model emphasizes innovation and quality, aiming to address the diverse needs of patients and healthcare providers across various sectors globally. By leveraging their expertise and extensive portfolio, Abbott strives to enhance patient outcomes and improve the overall quality of life.
MDxHealth SA is a biotech company that primarily focuses on developing and commercializing molecular diagnostic tests to assist healthcare professionals in making informed treatment decisions for cancer patients. Their business model revolves around providing accurate and actionable diagnostic information to improve patient outcomes and potentially reduce healthcare costs.
Sources:
Manhattan Scientifics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Manhattan Scientifics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
